Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Botulinum toxin in urology: evaluation using an evidence-based medicine approach

Nature Clinical Practice Urology volume 1, pages 31–37 (2004)Cite this article

Abstract

Clinical reports documenting the beneficial effects of botulinum toxin (BTX) to treat various lower urinary tract disorders of muscle spasticity (e.g. detrusor hyperreflexia, detrusor sphincter dyssynergia) have led to its expanded application in non-neurogenic conditions such as idiopathic detrusor overactivity, detrusor underactivity and benign prostatic hyperplasia (BPH). As greater numbers of investigators report their results utilizing this agent, it becomes more important that clinicians are able to synthesize and describe the findings of current clinical studies in a meaningful way. Evidence-based medicine is a platform on which investigations concerning a particular topic can be evaluated for their levels of scientific evidence, so that rational clinical recommendations can be formulated. This review article applies evidence-based practices to the use of BTX in common urologic conditions. Appreciating the benefits as well as limitations of currently available studies will hopefully drive the development of well-controlled, randomized studies of BTX, particularly in highly prevalent conditions such as idiopathic detrusor overactivity and BPH.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Illustration depicting nerve pathways targeted by botulinum toxin to treat lower urinary tract dysfunction.

Similar content being viewed by others

References

  1. Stewart WF et al. (2003) Prevalence and burden of overactive bladder in the Unites States. World J Urol 20: 327–336

    CAS  PubMed  Google Scholar 

  2. Perfetto EM and Morris LS (1996) Agency for Health Care Policy and Research clinical practice guidelines. Ann Pharmacother 30: 117–121

    Article  Google Scholar 

  3. Smith CP and Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171: 2128–2137

    Article  CAS  Google Scholar 

  4. Dykstra DD et al. (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 139: 919

    Article  CAS  Google Scholar 

  5. Mall V et al. (2001) Treatment of neuropathic bladder using botulinum toxin A in a 1-year old child with myelomeningocele. Pediatr Nephrol 16: 1161–1162

    Article  CAS  Google Scholar 

  6. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol 170: 1908–1912

    Article  CAS  Google Scholar 

  7. Dykstra DD and Sidi A (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 71: 24–26

    CAS  PubMed  Google Scholar 

  8. Petit H et al. (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36: 91–94

    Article  CAS  Google Scholar 

  9. Phelan MW et al. (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165: 1107–1110

    Article  CAS  Google Scholar 

  10. De Seze M et al. (2002) Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol 42: 56–62

    Article  CAS  Google Scholar 

  11. Schurch B et al. (1996) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia; a prospective study in 24 spinal cord injury patients. J Urol 155: 1023–1029

    Article  CAS  Google Scholar 

  12. McGuire EJ et al. (1981) The prognostic value of urodynamic testing in myelodysplastic patients. J Urol 126: 205–209

    Article  CAS  Google Scholar 

  13. Kim YH et al. (1998) Bladder leak point pressure: The measure for sphincterotomy success in spinal cord injured patients with external detrusor-sphincter dyssynergia. J Urol 159: 493–496

    Article  CAS  Google Scholar 

  14. Smith CP et al. (2002) Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct 13: 185–186

    Article  CAS  Google Scholar 

  15. Schurch B et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692–697

    Article  CAS  Google Scholar 

  16. Schulte-Baukloh H et al. (2003) Botulinum A-toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 44: 139–143

    Article  CAS  Google Scholar 

  17. Riccabona M et al. (2004) Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 171: 845–848

    Article  CAS  Google Scholar 

  18. Reitz A and Schurch B (2004) Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 171: 804–805

    Article  Google Scholar 

  19. Pistolesi D et al. (2004) Botulinum toxin type B for type A resistant bladder spasticity. J Urol 171: 802–803

    Article  CAS  Google Scholar 

  20. Dykstra D et al. (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14: 424–426

    Article  Google Scholar 

  21. Rapp DE et al. (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 63: 1071–1075

    Article  Google Scholar 

  22. Reitz A et al. (2004) European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510–515

    Article  CAS  Google Scholar 

  23. Giannantoni A et al. (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J Urol 172: 240–243

    Article  CAS  Google Scholar 

  24. Smith CP et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology, in press

  25. Maria G, et al. (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 62: 259–264

    Article  Google Scholar 

  26. Gallien P et al. (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79: 715–717

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scott Department of Urology at Baylor College of Medicine, Houston, Texas

    Christopher P Smith, George T Somogyi & Timothy B Boone

  2. Neurology Laboratory,

    Christopher P Smith, George T Somogyi & Timothy B Boone

Authors
  1. Christopher P Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George T Somogyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy B Boone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy B Boone.

Ethics declarations

Competing interests

CP Smith is a consultant and scientific inverstigator with Allergan Inc., Irvine, CA.

GT Somogyi is an investigator with Allergan Inc., Irvine, CA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, C., Somogyi, G. & Boone, T. Botulinum toxin in urology: evaluation using an evidence-based medicine approach. Nat Rev Urol 1, 31–37 (2004). https://doi.org/10.1038/ncpuro0034

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0034

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing